CONTEXT: Tight glucose control (TGC) to normal-for-age fasting blood glucose levels reduced morbidity and mortality in surgical adult and pediatric intensive care unit (ICU) patients. In adults, TGC did not affect the illness-induced alterations in thyroid hormones. With better feeding in children than in adult patients, we hypothesized that TGC in pediatric ICU patients reactivates the thyroid axis. OBJECTIVE: The aim of this study was to assess the impact of TGC on the thyroid axis in pediatric ICU patients and to investigate how these changes affect the TGC outcome benefit. DESIGN AND PATIENTS: We conducted a preplanned analysis of all patients not treated with thyroid hormone, dopamine, or corticosteroids who were included in a randomized controlled trial on TGC (n=700). MAIN OUTCOME MEASURES: Serum TSH, T4, T3, and rT3 were measured upon admission and on ICU day 3 or the last ICU day for patients discharged earlier. Changes from baseline were compared for the TGC and usual care groups. The impact on the outcome benefit of TGC was assessed with multivariable Cox proportional hazard analysis, correcting for baseline risk factors. RESULTS:TGC further lowered the T)/rT3 ratio (P=0.03), whereas TSH (P=0.09) and T4 (P=0.3) were unaltered. With TGC, the likelihood of earlier live discharge from the ICU was 19% higher at any time (hazard ratio, 1.190; 95% confidence interval, 1.010-1.407; P=0.03). This benefit was statistically explained by the further reduction of T3/rT3 with TGC because an increase in T3/rT3 was strongly associated with a lower likelihood for earlier live discharge (hazard ratio per unit increase, 0.863; 95% confidence interval, 0.806-0.927; P<0.0001). CONCLUSIONS:TGC further accentuated the peripheral inactivation of thyroid hormone. This effect, mimicking a fasting response, statistically explained part of the clinical outcome benefit of TGC.
RCT Entities:
CONTEXT: Tight glucose control (TGC) to normal-for-age fasting blood glucose levels reduced morbidity and mortality in surgical adult and pediatric intensive care unit (ICU) patients. In adults, TGC did not affect the illness-induced alterations in thyroid hormones. With better feeding in children than in adult patients, we hypothesized that TGC in pediatric ICU patients reactivates the thyroid axis. OBJECTIVE: The aim of this study was to assess the impact of TGC on the thyroid axis in pediatric ICU patients and to investigate how these changes affect the TGC outcome benefit. DESIGN AND PATIENTS: We conducted a preplanned analysis of all patients not treated with thyroid hormone, dopamine, or corticosteroids who were included in a randomized controlled trial on TGC (n=700). MAIN OUTCOME MEASURES: Serum TSH, T4, T3, and rT3 were measured upon admission and on ICU day 3 or the last ICU day for patients discharged earlier. Changes from baseline were compared for the TGC and usual care groups. The impact on the outcome benefit of TGC was assessed with multivariable Cox proportional hazard analysis, correcting for baseline risk factors. RESULTS: TGC further lowered the T)/rT3 ratio (P=0.03), whereas TSH (P=0.09) and T4 (P=0.3) were unaltered. With TGC, the likelihood of earlier live discharge from the ICU was 19% higher at any time (hazard ratio, 1.190; 95% confidence interval, 1.010-1.407; P=0.03). This benefit was statistically explained by the further reduction of T3/rT3 with TGC because an increase in T3/rT3 was strongly associated with a lower likelihood for earlier live discharge (hazard ratio per unit increase, 0.863; 95% confidence interval, 0.806-0.927; P<0.0001). CONCLUSIONS: TGC further accentuated the peripheral inactivation of thyroid hormone. This effect, mimicking a fasting response, statistically explained part of the clinical outcome benefit of TGC.
Authors: Dieter Mesotten; Patric J D Delhanty; Frank Vanderhoydonc; Kevin V Hardman; Frank Weekers; Robert C Baxter; Greet Van Den Berghe Journal: J Clin Endocrinol Metab Date: 2002-12 Impact factor: 5.958
Authors: Michael P Casaer; Dieter Mesotten; Greet Hermans; Pieter J Wouters; Miet Schetz; Geert Meyfroidt; Sophie Van Cromphaut; Catherine Ingels; Philippe Meersseman; Jan Muller; Dirk Vlasselaers; Yves Debaveye; Lars Desmet; Jasperina Dubois; Aime Van Assche; Simon Vanderheyden; Alexander Wilmer; Greet Van den Berghe Journal: N Engl J Med Date: 2011-06-29 Impact factor: 91.245
Authors: S Van der Geyten; E Van Rompaey; J P Sanders; T J Visser; E R Kühn; V M Darras Journal: Gen Comp Endocrinol Date: 1999-11 Impact factor: 2.822
Authors: Robin P Peeters; Pieter J Wouters; Ellen Kaptein; Hans van Toor; Theo J Visser; Greet Van den Berghe Journal: J Clin Endocrinol Metab Date: 2003-07 Impact factor: 5.958
Authors: Dieter Mesotten; Pieter J Wouters; Robin P Peeters; Kevin V Hardman; Jeff M Holly; Robert C Baxter; Greet Van den Berghe Journal: J Clin Endocrinol Metab Date: 2004-07 Impact factor: 5.958
Authors: Jodi M Maglich; Joe Watson; Patrick J McMillen; Bryan Goodwin; Timothy M Willson; John T Moore Journal: J Biol Chem Date: 2004-03-05 Impact factor: 5.157
Authors: Stéphane Leteurtre; Alain Martinot; Alain Duhamel; François Proulx; Bruno Grandbastien; Jacques Cotting; Ronald Gottesman; Ari Joffe; Jurg Pfenninger; Philippe Hubert; Jacques Lacroix; Francis Leclerc Journal: Lancet Date: 2003-07-19 Impact factor: 79.321